< Terug naar vorige pagina
Publicatie
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Tijdschriftbijdrage - Tijdschriftartikel
Tijdschrift: The Lancet Oncology
ISSN: 1470-2045
Issue: 2
Volume: 16
Pagina's: 152 - 60
Jaar van publicatie:2015
Trefwoorden:Aged, Androstenes, Antineoplastic Agents, Hormonal, Antineoplastic Combined Chemotherapy Protocols, Bone Neoplasms, Disease Progression, Double-Blind Method, Follow-Up Studies, Humans, Male, Neoplasm Staging, Prednisone, Prognosis, Prostatic Neoplasms, Castration-Resistant, Survival Rate